CE/CME

Prediabetes and Metabolic Syndrome: Current Trend

Author and Disclosure Information

Although accreditation for this CE/CME activity has expired, and the posttest is no longer available, you can still read the full article.

Expires September 30, 2016

Prediabetes and metabolic syndrome are growing health concerns in the United States and around the world. Lack of awareness of current recommendations may lead to delays in treatment and subsequent increases in diabetes and cardiovascular disease. Evidence-based recommendations for the management of prediabetes and metabolic syndrome focus on lifestyle changes. The most effective strategies for the prevention of type 2 diabetes and management of metabolic syndrome are reviewed here.


 

References


CE/CME No: CR-1510

PROGRAM OVERVIEW
Earn credit by reading this article and successfully completing the posttest and evaluation. Successful completion is defined as a cumulative score of at least 70% correct.

EDUCATIONAL OBJECTIVES
• Explain the pathophysiology of and risk factors for diabetes.
• Identify the current diagnostic criteria for prediabetes.
• Discuss health risks associated with metabolic syndrome.
• Describe the management of prediabetes and metabolic syndrome.

FACULTY
Annie Abraham is an Assistant Clinical Professor at Texas Woman's University, Dallas and Doctor of Nursing Practice candidate at Texas Christian University, Fort Worth, Texas. Susan Chaney is a Professor, Allison Huffman is an Assistant Clinical Professor, and Kathryn Kremer is an Associate Clinical Professor, at Texas Woman’s University, Dallas.
The authors have no financial relationships to disclose.

ACCREDITATION STATEMENT

This program has been reviewed and is approved for a maximum of 1.0 hour of American Academy of Physician Assistants (AAPA) Category 1 CME credit by the Physician Assistant Review Panel. [NPs: Both ANCC and the AANP Certification Program recognize AAPA as an approved provider of Category 1 credit.] Approval is valid for one year from the issue date of October 2015.

Article begins on next page >>

Pages

Recommended Reading

In reply: Eruptive xanthoma
Type 2 Diabetes ICYMI
Poor glycemic control upped chances of coronary events after CABG
Type 2 Diabetes ICYMI
High troponin T level doubles CVD risk
Type 2 Diabetes ICYMI
VIDEO: Young hypertensives: Cut back on the caffeine
Type 2 Diabetes ICYMI
VIDEO: Newer type 2 diabetes drugs pose no significant heart failure risk
Type 2 Diabetes ICYMI
VIDEO: Newer Type 2 Diabetes Drugs Pose No Significant Heart Failure Risk
Type 2 Diabetes ICYMI
HbA1c aids prediction of atherosclerotic CVD
Type 2 Diabetes ICYMI
ESC: Further data indicate no excess heart failure risk with lixisenatide or sitagliptin
Type 2 Diabetes ICYMI
EASD: SGLT2 inhibitor empagliflozin cuts CV risk in patients with type 2 diabetes
Type 2 Diabetes ICYMI
Empagliflozin’s triumph respins FDA’s diabetes drug mandate
Type 2 Diabetes ICYMI

Related Articles

  • Article

    Mumps–It’s Back!

    Although accreditation for this CE/CME activity has expired, and the posttest is no longer available, you can still read the full article.

  • Article

    Ebola: Lessons from the Latest Pandemic

    Although accreditation for this CE/CME activity has expired, and the posttest is no longer available, you can still read the full article.

    ...